The antioxidant and anti-inflammatory activities of nutraceuticals are current research topics in the area of the management and prevention of oxidative stress-related diseases. This issue includes preclinical research aimed to evaluate the effect of pure compounds (P. ) also show that constituents in the huskless barley extract and sweet potato leaf polyphenols enable the reduction of monocyte chemotactic protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and/or nuclear factor-kappa B (NF-κB) in human endothelial cells, which are in line with the concerted modulation of nuclear factor-erythroid 2-related factor 2 (Nrf2) and NF-κB in inflammation and oxidative stress. However, H. Sun et al. note that the inhibitory effect of individual polyphenolic compounds present in sweet potato leaves on the intracellular ROS is not related to their antioxidant activity, suggesting that the polyphenolic compounds may attenuate the sources of ROS generation. However, the precaution must be taken in the extrapolation of the in vitro findings to humans because most absorbed polyphenols are present in metabolized forms. Moreover, the protein-rich extract of Oviductus ranae (PEOR) displays a strong antioxidant effect in ethanol-induced oxidative stress mice model, despite its weak radical scavenging and ferric-reducing capacities in vitro ( On the contrary, in rats treated with resveratrol, the decrease in nitric oxide and lipoperoxidation in the cardiac tissues is not accompanied by the induction of antioxidant enzymes (CAT and SOD).
In addition to the antioxidant and anti-inflammatory effects of huskless barley extracts, the polysaccharide extracts inhibit the synthesis of angiotensin-converting enzyme (ACE) in vitro (Z. Liao et al.), with the alkaline extracts being more pronounced probably due to the abundance of phenolic compounds as compared to the water extracts. The modulation of ACE expression is also found with blueberry anthocyanins and anthocyanidins (W. Huang et al.) , but the effect is divergent, for example, malvidin downregulates the expression and some malvidin glycosides result in the upregulation.
Therefore, caution must be taken when interpreting preclinical data that evaluate the effects of natural functional compounds on antioxidation, anti-inflammation, and other pharmacological actions. In this context, E. Toti et al. (Non-Provitamin A and Provitamin A Carotenoids as Immunomodulators: Recommended Dietary Allowance, Therapeutic Index, or Personalized Nutrition?) underscore that preclinical evidence must be confirmed in human interventions before any recommendations can be made for carotenoids. This point can also be extended to polyphenols and other dietary agents. For example, both β-carotene and lycopene at pharmacological doses affect immune functions. However, large clinical trials do not support β-carotene supplementation. On the other hand, although lycopene supplementation for regulation of immunity seems more promising than β-carotene, more robust human studies with adequate power and duration are needed in order to confirm this effect.
In conclusion, we hope that this special issue adds knowledge of preclinical data of the potential health effects of nutraceuticals. However, these results only provide supports for future studies, particularly human trials, but not give indications for supplementation.
